Drug Discovery World

MAY 9, 2024

Mekonos, a company working towards cell engineering on a chip, has entered into a partnership agreement with Accelerated Bio to codevelop a new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.

Engineer 64

Engineer Gene Editing Manufacturing Gene 64

BioTech 365

AUGUST 20, 2021

Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting … Continue reading →

Gene Editing 40

Gene Editing Engineer Genome Genomics 40

BioTech 365

OCTOBER 19, 2021

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs … Continue reading →

Gene Editing 40

Gene Editing Engineer Licensing Licensing 40

pharmaphorum

OCTOBER 4, 2022

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The post AstraZeneca pays record 660% premium for gene editing company LogicBio appeared first on.

Gene Editing 64

Gene Editing Gene Genome Genomics 64

STAT News

MARCH 16, 2023

They were stubborn, inflexible enzymes, requiring endless engineering. Many of these once beloved tools were tossed aside when CRISPR came along, having helped few actual patients but driven plenty of graduate students to exhaustion. CRISPR, by contrast, lets you cut almost any stretch of DNA with a simple chemical code.

Gene Editing 98

Gene Editing Gene DNA Genome 98

STAT News

MARCH 1, 2023

Genome editing summits are generally friendly, nerdy affairs, but for a moment at a Lisbon hotel last June, the conversation at the FASEB genome engineering conference grew tense.

Gene Editing 119

Gene Editing Genetic Disease Genome Genomics 119

Scienmag

JANUARY 12, 2021

Martins Scientists have used gene-editing advances to achieve a tenfold increase in the production of super-bug targeting formicamycin antibiotics. Credit: Dr Dino J. The John Innes Centre researchers used the technology to create a new strain of Streptomyces formicae bacteria which over-produces the medically promising molecules.

Gene Editing 53

Gene Editing Gene Bacteria Scientist 53

Pharmaceutical Technology

NOVEMBER 16, 2022

ElevateBio has entered a partnership with Affini-T Therapeutics to progress the latter’s engineered TCR-T therapies focused on Kirsten rat sarcoma viral oncogene homolog (KRAS), a dominant oncogenic driver mutation in solid tumours.

Development 246

Development Gene Therapy Engineer Gene Editing 246

Scienmag

APRIL 6, 2021

Credit: Photo by Hisashi Urashima A statistically rigorous survey of Japanese consumers has found that they have more negative opinions about the use of new gene-editing techniques on livestock than they do about use of the same technologies on vegetables.

Gene Editing 52

Gene Editing Gene Engineer 52

pharmaphorum

OCTOBER 8, 2020

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. Scribe has designed, engineered and tested thousands of evolved CRISPR enzymes to build an advanced platform for creating breakthrough in vivo treatments,” said Oakes.

Gene Editing 53

Gene Editing Gene In-Vivo Clinical Trials 53

Pharmaceutical Technology

MAY 25, 2023

ElevateBio has raised $401m in a Series D financing round for advancing its technology platforms to expedite the design, production and development of cell and gene therapies. The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform.

Gene Therapy 243

Gene Therapy Gene Gene Editing Manufacturing 243

BioTech 365

SEPTEMBER 3, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Researchers develop an engineered ‘mini’ CRISPR genome editing system.The common analogy for CRISPR gene editing is that it works like molecular scissors, cutting out select sections of … Continue reading → (..)

Engineer 40

Engineer Genome Genomics Gene Editing 40

BioPharma Reporter

NOVEMBER 2, 2020

PerkinElmer will acquire UK cell engineering company Horizon Discovery, expanding its portfolio with gene editing and gene modulation tools.

Gene Editing 98

Gene Editing Engineer Gene Development 98

Pharmaceutical Technology

MAY 12, 2023

The team then engineered the phages through gene editing to improve their targeting ability. The team, based at SNIPR Biome, screened 162 naturally occurring phages (viruses that kill specific bacteria) and found that eight showed promise in targeting E coli.

Development 246

Development Bacteria Research Gene Editing 246

BioTech 365

DECEMBER 23, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Genetic engineering without unwanted side effects helps fight parasites.Modified CRISPR-Cas9 gene editing scissors are enabling researchers at the University of Zurich to make alterations to the genetic … Continue reading (..)

Genetic Engineering 40

Genetic Engineering Engineer Genetics Gene Editing 40

Drug Discovery World

JULY 8, 2024

The last few days have seen some interesting developments related to gene editing, including the discovery of a new mechanism for genetic programming and evidence in favour of redosing CRISPR-based therapies, as well as significant investment and new indications for gene therapies.

Gene Editing 59

Gene Editing Gene Therapy Gene Genetics 59

Drug Discovery World

MAY 5, 2023

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. In contrast to DNA-based reprogramming and gene editing, the mRNA-based approach does not expose cells to expensive and potentially harmful viruses or DNA vectors.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Drug Discovery World

OCTOBER 10, 2023

The National Institutes of Health has awarded the first phase of a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases. The two diseases being targeted in the project are Angelman syndrome and H1-4 (HIST1H1E) syndrome.

Gene Editing 52

Gene Editing Development Drugs Clinical Trials 52

Drug Discovery World

JANUARY 9, 2023

Using gene engineering, we are repurposing cancer cells to develop a therapeutic that kills tumour cells and stimulates the immune system to both destroy primary tumors and prevent cancer.” . CRISPR-Cas9 gene editing .

Scientist 52

Scientist Gene Editing Engineer Gene 52

BioPharma Reporter

MARCH 2, 2021

The gene-editing and genome-engineering company, eGenesis, today announced the completion of a US$125m Series C financing round.

Gene Editing 52

Gene Editing Medicine Genome Genomics 52

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Pharmaceutical Technology

MARCH 2, 2023

The therapeutic candidate comprises allogeneic NK cells genetically engineered to express chimeric antigen receptors (CAR-NK) targeting cells CD33. The company develops gene-editing organ transplantation technology. Hangzhou Qihan Biotechnology overview Hangzhou Qihan Biotechnology is a healthcare company.

Gene Editing 100

Gene Editing Genetic Engineering Engineer Clinical Trials 100

pharmaphorum

MAY 7, 2021

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. It’s at the forefront of gene editing although the technology has spawned rivals including Intellia Therapeutics, Caribou Biosciences, Sangamo Therapeutics and Mammoth Biosciences.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

Drug Discovery World

DECEMBER 8, 2023

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. ONK and NAYA plan to assess several combination therapies in preclinical cancer models in 2024 prior to subsequently exploring initiating clinical trials.

Antibody 52

Antibody Gene Editing Clinical Trials Clinical Trials 52

Drug Discovery World

MARCH 22, 2023

The research team, including lead author David Mai, a Bioengineering graduate student in the School of Engineering and Applied Science, hypothesised that targeting the related, but independent Roquin-1 regulator at the same time could boost responses further. In some mice, it also led to overproduction of lymphocytes, causing toxicity.

Gene Editing 52

Gene Editing Gene Engineer Regulation 52

Pharmaceutical Technology

AUGUST 26, 2022

This centre will be equipped with its supporting technologies, such as gene editing induced pluripotent stem cell (iPSC) and cell, vector and protein engineering expertise.

Gene Therapy 162

Gene Therapy Gene Editing Gene Manufacturing 162

Pharmaceutical Technology

APRIL 28, 2023

EDIT-301 is made of patient-derived CD34+ haematopoietic stem and progenitor cells, which are edited using CRISPR at the gamma globin gene (HBG1 and HBG2) promoter sites using a proprietary engineered AsCas12a nuclease, per the company’s website. This increases the expression of fetal haemoglobin.

Gene Therapy 264

Gene Therapy Drugs Gene Gene Editing 264

Drug Discovery World

JULY 19, 2024

The scientists demonstrate that gene editing of LT-HSCs in the gels is possible and believe the findings could provide a new way to test new drugs or techniques for treating blood disorders, such as sickle cell disease, and blood cancers, reducing the reliance on animal models, which are increasingly poor predictors of drug outcomes.

Drugs 52

Drugs In-Vitro Gene Editing Scientist 52

Drug Discovery World

JUNE 7, 2023

The disease-relevant mutation is engineered into bit.bio’s human ioWild Type  cells using CRISPR/Cas9 gene editing. The company’s new Custom ioDisease Model Cells offering lets scientists choose the disease-relevant mutation they’re interested in.

Gene Editing 52

Gene Editing Scientist Gene Engineer 52

BioTech 365

APRIL 9, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: New, reversible CRISPR method can control gene expression while leaving underlying DNA sequence unchanged.Over the past decade, the CRISPR-Cas9 gene editing system has revolutionized genetic engineering, allowing … Continue (..)

Gene Expression 40

Gene Expression DNA Gene Editing Gene 40

Drug Discovery World

NOVEMBER 27, 2023

Upstream cell line development has seen notable progress with recent advances in cell line engineering, particularly in enhancing gene of interest integration specificity, clone selection, and production efficiency. Next-generation engineering tools, such as gene editing have enabled knock-out cell lines with enhanced characteristics.

Production 59

Production Engineer Gene Editing Gene 59

Drug Discovery World

JUNE 30, 2023

The patent granted by EPO specifically covers CISH KO NK cells, and cancer therapies that utilise NK cells with CISH KO, as well as NK cells engineered with the foundational CISH KO in combination with IL-15 (soluble or engineered), TGFβR2 KO, or TGFβR2 KO and IL-15 (soluble or engineered).

Gene Editing 52

Gene Editing Engineer Licensing Licensing 52

Scienmag

JANUARY 5, 2022

SAN FRANCISCO, CA—January 5, 2021—Over the past decade, the CRISPR genome-editing system has revolutionized molecular biology, giving scientists the ability to alter genes inside living cells for research or medical applications. Credit: Photo: Michael Short/Gladstone Institutes […].

Gene 87

Gene Gene Editing Research Genome 87

Drug Discovery World

NOVEMBER 1, 2023

At the moment, we are focused on gene editing tools, and specifically CRISPR nucleases, trying to design strategies that allow us to use them more safely and effectively. Our goal is to develop strategies that allow us to understand how they work and how they find their targets, so we can hopefully improve them.

Gene Editing 59

Gene Editing Research Gene Genome 59

BioTech 365

OCTOBER 22, 2020

-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, Fla. & & STOCKHOLM–(BUSINESS WIRE)–#celltherapy–Vycellix, Inc.,

Gene Editing 52

Gene Editing Immune Response Life Science Engineer 52

WCG Clinical

NOVEMBER 17, 2023

Since then, however, certain genetic engineering technologies (e.g., CRISPR-based gene editing) have advanced to the point where cellular genomes can be edited without using viral vectors or any other materials subject to the NIH Guidelines and without integration of rsNA into the chromosome.

Genome 52

Genome Genomics Gene Editing Genetic Engineering 52

Drug Discovery World

JUNE 22, 2023

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights. The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52